← The Wire
EDITNasdaq
Editas Medicine, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1650664
Editas Medicine develops genomic medicines using CRISPR gene editing to treat serious diseases
red 8-K · 90d
$384M
Market cap
$3.20
Last close
+12.3%
1D
+14.3%
5D
3.0M
Volume
Price · last 39 sessions+6.7%
May 4L $2.36 · H $3.57Jun 29
223
Total filings
Jun 18, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 18, 2026424B5424B5May 26, 20268-KMaterial Agreement · Company UpdateMay 26, 20268-KCompany UpdateMay 26, 2026424B5424B5May 26, 20268-KReg FD Disclosure · Company UpdateMay 26, 20268-KReg FD Disclosure · Company UpdateMay 14, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 5, 2026DEFA14ADEFA14AApr 28, 2026DEF 14ADEF 14AApr 28, 20268-KAuditor ChangeApr 7, 20268-KReg FD Disclosure · Company UpdateMar 27, 202610-K10-KMar 9, 20268-KResults of OperationsMar 9, 202610-Q10-QNov 10, 20258-KResults of OperationsNov 10, 20258-KReg FD Disclosure · Company UpdateOct 9, 20258-KReg FD Disclosure · Company UpdateSep 2, 202510-Q10-QAug 12, 20258-KResults of OperationsAug 12, 20258-KReg FD Disclosure · Company UpdateJun 12, 20258-KExecutive Change · Bylaw AmendmentJun 2, 20258-KReg FD Disclosure · Company UpdateMay 14, 20258-KReg FD Disclosure · Company UpdateMay 13, 202510-Q10-QMay 12, 20258-KResults of OperationsMay 12, 2025DEFA14ADEFA14AApr 15, 2025DEF 14ADEF 14AApr 15, 20258-KExecutive ChangeMar 20, 202510-K10-KMar 5, 20258-KResults of OperationsMar 5, 20258-KResults of Operations · Reg FD DisclosureJan 13, 20258-KExecutive ChangeDec 17, 20248-KExecutive Change · Exit / Disposal CostsDec 12, 20248-KBylaw Amendment · Reg FD DisclosureDec 10, 202410-Q10-QNov 4, 20248-KResults of OperationsNov 4, 20248-KResults of Operations · Reg FD DisclosureOct 22, 20248-KMaterial Agreement · New Debt / ObligationOct 4, 202410-Q10-QAug 7, 20248-KResults of OperationsAug 7, 20248-KExecutive ChangeJun 27, 20248-KReg FD Disclosure · Company UpdateJun 14, 20248-KShareholder VoteMay 31, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 2024DEFA14ADEFA14AApr 16, 2024DEF 14ADEF 14AApr 16, 202410-K10-KFeb 28, 20248-KResults of OperationsFeb 28, 20248-KReg FD Disclosure · Company UpdateDec 13, 20238-KReg FD Disclosure · Company UpdateDec 11, 20238-KExecutive ChangeNov 22, 202310-Q10-QNov 3, 20238-KResults of OperationsNov 3, 20238-KExecutive ChangeOct 10, 2023SC 13GSC 13GAug 4, 202310-Q10-QAug 2, 20238-KResults of OperationsAug 2, 20238-KMaterial Agreement · Company UpdateJun 15, 2023424B5424B5Jun 15, 2023424B5424B5Jun 14, 20238-KReg FD Disclosure · Company UpdateJun 9, 20238-KShareholder VoteJun 5, 20238-KExecutive ChangeMay 17, 202310-Q10-QMay 5, 20238-KResults of OperationsMay 5, 2023DEFA14ADEFA14AApr 18, 2023DEF 14AFORM DEF 14AApr 18, 20238-KExecutive ChangeApr 13, 20238-KExecutive Change · Bylaw AmendmentMar 14, 202310-K10-KFeb 22, 20238-KResults of OperationsFeb 22, 20238-KExecutive ChangeJan 9, 20238-KCompany UpdateDec 6, 20228-KCompany UpdateNov 17, 202210-Q10-QNov 2, 20228-KResults of OperationsNov 2, 202210-Q10-QAug 3, 2022
Insider Activity
In the 90 days to Mar 3, 2026: 3 sold $28K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3, 2026 | O'Neill Gilmore NeilCEO | Sell | 5,394 | $2.02 | $11K |
| Mar 3, 2026 | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sell | 749 | $2.02 | $2K |
| Mar 3, 2026 | Parison AmySVP, Chief Financial Officer | Sell | 474 | $2.02 | $957 |
| Dec 3, 2025 | O'Neill Gilmore NeilCEO | Sell | 5,603 | $2.15 | $12K |
| Dec 3, 2025 | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | Sell | 713 | $2.15 | $2K |
| Dec 3, 2025 | Parison AmySVP, Chief Financial Officer | Sell | 461 | $2.15 | $991 |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance